The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas
Authors:
Open Access
- 16 October 2001
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 85 (8) , 1153-1156
Abstract
Infection with the human papillomavirus is an important co-factor in the development of cervical carcinomas. Accordingly, HPV DNA is recognised in most of these tumours. Polymorphism of the p53 gene, codon 72, is also considered a risk factor in the development of cervical carcinoma. However, this finding is contradicted by several observers. In the present investigation, 111 cases of adenocarcinoma of the cervix collected through the Swedish Cancer Registry and 188 controls (females with normal cytology at organised gynaecological screening) were analysed with regard to p53, codon 72, polymorphism using a PCR- and SSCP-based technique. In the controls, 9% showed pro/pro, 44% pro/arg and 47% arg/arg, whereas in the invasive adenocarcinomas, the corresponding figures were 0%, 29% and 71%, respectively. The difference was statistically significant (P = 0.001). HPV DNA was identified in 86 tumours (HPV 18 in 48, HPV 16 in 31 and HPV of unknown type in 7 cases) and 25 tumours were HPV negative. The p53, codon 72, genotypes observed in HPV-positive and HPV-negative cervical adenocarcinomas were not statistically different (P = 0.690). The results indicate that women homozygotic for arg/arg in codon 72 of the p53 gene are at an increased risk for the development of cervical adenocarcinomas. However, this genetic disposition seems to be unrelated to the HPV infection. © 2001 Cancer Research Campaign http://www.bjcancer.comKeywords
This publication has 30 references indexed in Scilit:
- The role of human papillomavirus in cervical adenocarcinoma carcinogenesisEuropean Journal of Cancer, 2001
- Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus.2000
- P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation.2000
- Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesionsBritish Journal of Cancer, 2000
- Trends in cancer of the cervix uteri in Sweden following cytological screeningBritish Journal of Cancer, 1999
- Rapid Test for Identification of a Human Papillomavirus 16 E6 L83V VariantDiagnostic Molecular Pathology, 1999
- Pap smear screening and changes in cervical cancer mortality in SwedenInternational Journal of Gynecology & Obstetrics, 1994
- The presentation of adenocarcinoma of the uterine cervixCancer, 1993
- Typing of human papillomaviruses by polymerase chain reaction amplification with L1 consensus primers and RFLP analysisMolecular and Cellular Probes, 1992
- Diagnosis of Sickle Cell Anemia and β-Thalassemia with Enzymatically Amplified DNA and Nonradioactive Allele-Specific Oligonucleotide ProbesNew England Journal of Medicine, 1988